NABi, a novel β-sheet breaker, inhibits Aβ aggregation and neuronal toxicity

Therapeutic implications for Alzheimer's disease

Ja Young Jang, Hyangshuk Rhim, Seongman Kang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Amyloid beta (Aβ) aggregates are an important therapeutic target for Alzheimer's disease (AD), a fatal neurodegenerative disease. To date, AD still remains a big challenge due to no effective treatments. Based on the property that Aβ aggregates have the cross-β-structure, a common structural feature in amyloids, we systemically designed the Aβ-aggregation inhibitor that maintains Aβ-interacting ability but removes toxic part from SOD1 (superoxide dismutase 1)-G93A. We identified NABi (Natural Aβ Binder and Aβ-aggregation inhibitor) composed of β2–3 strands, a novel breaker of Aβ aggregation, which does not self-aggregate and has no cytotoxicity at all. The NABi blocks Aβ-fibril formation in vitro and in vivo and prevents neuronal cell death, a hallmark of AD pathogenesis. Such anti-amyloidogenic properties can provide novel strategies for treating AD. Furthermore, our study provides molecular insights into the design of amyloidogenic inhibitors to cure various neurodegenerative and amyloid-associated diseases, as NABi would regulate aggregation of other toxic β-sheet proteins other than Aβ.

Original languageEnglish
Pages (from-to)71-80
Number of pages10
JournalBiochimica et Biophysica Acta - General Subjects
Volume1862
Issue number1
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Toxicity
Alzheimer Disease
Agglomeration
Amyloid
Poisons
Aptitude
Neurodegenerative diseases
Therapeutics
Neurodegenerative Diseases
Cell death
Cytotoxicity
Cell Death
Superoxide Dismutase
Binders
Proteins

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology

Cite this

NABi, a novel β-sheet breaker, inhibits Aβ aggregation and neuronal toxicity : Therapeutic implications for Alzheimer's disease. / Jang, Ja Young; Rhim, Hyangshuk; Kang, Seongman.

In: Biochimica et Biophysica Acta - General Subjects, Vol. 1862, No. 1, 01.01.2018, p. 71-80.

Research output: Contribution to journalArticle

@article{318b53beded84aa98b948ccc27258e1c,
title = "NABi, a novel β-sheet breaker, inhibits Aβ aggregation and neuronal toxicity: Therapeutic implications for Alzheimer's disease",
abstract = "Amyloid beta (Aβ) aggregates are an important therapeutic target for Alzheimer's disease (AD), a fatal neurodegenerative disease. To date, AD still remains a big challenge due to no effective treatments. Based on the property that Aβ aggregates have the cross-β-structure, a common structural feature in amyloids, we systemically designed the Aβ-aggregation inhibitor that maintains Aβ-interacting ability but removes toxic part from SOD1 (superoxide dismutase 1)-G93A. We identified NABi (Natural Aβ Binder and Aβ-aggregation inhibitor) composed of β2–3 strands, a novel breaker of Aβ aggregation, which does not self-aggregate and has no cytotoxicity at all. The NABi blocks Aβ-fibril formation in vitro and in vivo and prevents neuronal cell death, a hallmark of AD pathogenesis. Such anti-amyloidogenic properties can provide novel strategies for treating AD. Furthermore, our study provides molecular insights into the design of amyloidogenic inhibitors to cure various neurodegenerative and amyloid-associated diseases, as NABi would regulate aggregation of other toxic β-sheet proteins other than Aβ.",
author = "Jang, {Ja Young} and Hyangshuk Rhim and Seongman Kang",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.bbagen.2017.10.014",
language = "English",
volume = "1862",
pages = "71--80",
journal = "Biochimica et Biophysica Acta - General Subjects",
issn = "0304-4165",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - NABi, a novel β-sheet breaker, inhibits Aβ aggregation and neuronal toxicity

T2 - Therapeutic implications for Alzheimer's disease

AU - Jang, Ja Young

AU - Rhim, Hyangshuk

AU - Kang, Seongman

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Amyloid beta (Aβ) aggregates are an important therapeutic target for Alzheimer's disease (AD), a fatal neurodegenerative disease. To date, AD still remains a big challenge due to no effective treatments. Based on the property that Aβ aggregates have the cross-β-structure, a common structural feature in amyloids, we systemically designed the Aβ-aggregation inhibitor that maintains Aβ-interacting ability but removes toxic part from SOD1 (superoxide dismutase 1)-G93A. We identified NABi (Natural Aβ Binder and Aβ-aggregation inhibitor) composed of β2–3 strands, a novel breaker of Aβ aggregation, which does not self-aggregate and has no cytotoxicity at all. The NABi blocks Aβ-fibril formation in vitro and in vivo and prevents neuronal cell death, a hallmark of AD pathogenesis. Such anti-amyloidogenic properties can provide novel strategies for treating AD. Furthermore, our study provides molecular insights into the design of amyloidogenic inhibitors to cure various neurodegenerative and amyloid-associated diseases, as NABi would regulate aggregation of other toxic β-sheet proteins other than Aβ.

AB - Amyloid beta (Aβ) aggregates are an important therapeutic target for Alzheimer's disease (AD), a fatal neurodegenerative disease. To date, AD still remains a big challenge due to no effective treatments. Based on the property that Aβ aggregates have the cross-β-structure, a common structural feature in amyloids, we systemically designed the Aβ-aggregation inhibitor that maintains Aβ-interacting ability but removes toxic part from SOD1 (superoxide dismutase 1)-G93A. We identified NABi (Natural Aβ Binder and Aβ-aggregation inhibitor) composed of β2–3 strands, a novel breaker of Aβ aggregation, which does not self-aggregate and has no cytotoxicity at all. The NABi blocks Aβ-fibril formation in vitro and in vivo and prevents neuronal cell death, a hallmark of AD pathogenesis. Such anti-amyloidogenic properties can provide novel strategies for treating AD. Furthermore, our study provides molecular insights into the design of amyloidogenic inhibitors to cure various neurodegenerative and amyloid-associated diseases, as NABi would regulate aggregation of other toxic β-sheet proteins other than Aβ.

UR - http://www.scopus.com/inward/record.url?scp=85032930671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032930671&partnerID=8YFLogxK

U2 - 10.1016/j.bbagen.2017.10.014

DO - 10.1016/j.bbagen.2017.10.014

M3 - Article

VL - 1862

SP - 71

EP - 80

JO - Biochimica et Biophysica Acta - General Subjects

JF - Biochimica et Biophysica Acta - General Subjects

SN - 0304-4165

IS - 1

ER -